Photo of Seung-Oe Lim
Seung-Oe Lim
Assistant Professor of Medicinal Chemistry and Molecular Pharmacology
Phone: 765-494-3531
Specialization: Cancer, Immuno-oncology, Immunotherapy, Alzheimer's disease
B.S. 03/1997 - 02/2001 Seoul National University, Republic of Korea
M.S. 03/2001 - 02/2003 Seoul National University, Republic of Korea
Ph.D. 09/2003 - 08/2008 Seoul National University, Republic of Korea
Postdoc 09/2008 - 01/2010 Seoul National University, Republic of Korea
Postdoc 03/2010 - 01/2016 UT MD Anderson Cancer Center, Houston, TX, US
Instructor 02/2016 - 06/2017 UT MD Anderson Cancer Center, Houston, TX, US

Currently Accepting Students

Cancer Biology, Immuno-oncology, Immunotherapy, antibody engineering, Alzheimer's disease

Lab Members
Alyssa Min Jung Kim (Graduate Research Assistant)
Jiyeun Lee (Research Assistant)

Research in the Lim lab focuses on identification of regulatory mechanism of anti-tumor immunity in several types of cancers in particular breast cancer. Based on the mechanism, we focus on developing strategies that enhance therapeutic efficacy of immunotherapy and identification of new druggable target to overcome immune checkpoint blockade resistance.


MCMP 42200 Immunology

Representative Publications
  1. Lim SO, Park SJ, Kim W, Park SG, Kim HJ, Kim YI, Sohn TS, Noh JH, Jung G. "Proteome analysis of hepatocellular carcinoma" Biochem Biophys Res Commun 2002 Mar 8; 291(4):1031-7.
  2. 2. Park SG, Lm SO, Jung G. "Binding Site Analysis of Human HBV Pol for Molecular Chaperonin, Hsp60" Virology 2002 Jun; 283, 116-23.
  3. 3. Kim W* and Lim SO*, Kim JS, Ryu YH, Byeon JY, Kim HJ, Kim YI, Heo JS, Park YM, Jung G. "Comparison of Proteome between Hepatitis B Virus- and Hepatitis C Virus- associated Hepatocellular Carcinoma" Clinical Cancer Research 2003 Nov 15;9(15):5493-500. *Co-first author
  4. 4. Yoo JH, Lim SO. “DFO treatment of HepG2.2.15 induces proteomic changes that may inhibit viral particle secretion” Korean Journal of Genetics 2004 26(4): 397-403.
  5. 5. Lim SO, Park SG, Yoo JH, Park YM, Kim HJ, Jang KT, Cho JW, Yoo BC, Park CK, Jung G. “Expression of Heat Shock Proteins in Hepatitis B Virus-Related Hepatocellular Carcinomas and Dysplastic Nodules” World Journal of Gastroenterology 2005 Apr 14;11(14):2072-9.
  6. 6. Lee SH, Park SG, Lim SO, Jung G. "The hepatitis B virus X protein up-regulates lymphotoxin a expression in hepatocytes" BBA 2005 Jun; 1741:75-84.
  7. 7. Park SG, Ryu HM, Lim SO, Kim YI, Hwang SB, Jung " Interferon-γ Inhibits Hepatitis B Virus-Induced NF-κB Activation through Nuclear Localization of NF-κB-inducing Kinase " Gastroenterology 2005 Jun;128(7):2042-53.
  8. 8. Lee HH, Kim HS, Kang JY, Lee BI, Ha JY, Yoon HJ, Lim SO, Jung G, Suh SW "Crystal structure of human nucleophosmin-core reveals plasticity of the pentamer-pentamer interface." Proteins 2007 Aug 24;69(3):672-678.
  9. 9. Gu JM, Lim SO, Oh SJ, Yoon SM, Seong J, Jung G. “HBx modulates iron regulatory protein 1-mediated iron metabolism via reactive oxygen species” Virus Research 2008 Feb 8; 133,167-177.
  10. 10. Gu JM, Lim SO, Park YM, Jung “A novel splice variant of occludin deleted in exon 9 and its role in cell apoptosis and invasion” FEBS J 2008 Jun;275(12):3145-56. Epub 2008 May 16.
  11. 11. Lim SO, Gu JM, Kim MS, Kim HS, Park YN, Park CK, Cho JW, Park YM, Jung “Epigenetic Changes induced by reactive oxygen species in Hepatocellular Carcinoma: Methylation of the E-cadherin Promoter” Gastroenterology 2008 Dec; 135(6):2128-2140. Epub 2008 Jul 31.
  12. Lim SO, Kim HT, Jung G. “p53 Inhibits Tumor Cell Invasion via the Degradation of Snail Protein in Hepatocellular carcinoma FEBS Lett. 2010 Jun 3;584(11):2427-32. Epub 2010 Apr 21.
  13. 13. Min JY, Lim SO, Jung G. “Downregulation of catalase by reactive oxygen species via hypermethylation of CpG island II on the catalase promoter.” FEBS Lett. 2010 Jun 3;584(11):2427-32. Epub 2010 Apr 21.
  14. 14. Hsieh A, Kim HS, Lim SO, Yu DY, Jung G. “Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling” Cancer Lett. 2011 Jan 28;300(2):162-72. Epub 2010 Oct 23.
  15. 15. Song H, Li CW, Labaff AM, Lim SO, Li LY, Kan SF, Chen Y, Zhang K, Lang J, Xie X, Wang Y, Huo LF, Hsu SC, Chen X, Zhao Y, Hung MC. “Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors” Biochem Biophys Res Commun. 2011 Jan 7;404(1):68-73. Epub 2010 Nov 19.
  16. Lim SO, Park YM, Kim HS, Quan X, Yoo JE, Park YN, Choi GH, Jung G. “Notch1 differentially regulates oncogenesis by wild type p53 overexpression and p53 mutation in grade III hepatocellular carcinoma” Hepatology 2011 Apr;53(4):1382-1392.
  17. Quan X, Lim SO, Jung G. “Reactive oxygen species downregulate catalase expression via methylation of a CpG Island in the Oct-1 promoter” FEBS Lett. 2011 Nov 4;585(21):3436-41. Epub 2011 Oct 6.
  18. Lim SO, Kim HS, Quan X, Ahn SM, Kim H, Hsieh D, Seong JK, Jung G. “Notch1 binds and induces degradation of Snail in hepatocellular carcinoma” BMC Biology 2011 Nov 30; 9(1):83.
  19. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, Labaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, Hung MC. Epithelial-Mesenchymal Transition Induced by TNF-α Requires NF-κB-Mediated Transcriptional Upregulation of Twist1Cancer Res. 2012 Mar 1;72(5):1290-1300. Epub 2012 Jan 17
  20. Kim HS, Jeong H, Lim SO, Jung G.Snail inhibits Notch1 intracellular domain mediated transcriptional activation via competing with MAML1” Biochem Biophys Res Commun 2013 Mar 29; 433(1): 6-10.
  21. Shen J, Xia W, Khotskaya Y, Huo LF, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH, Hsu J, Lam YC, James B, Liu X, Liu CG, Patel D, Wu Y, Hung MC, “EGFR Modulates miRNA Maturation in Response to Hypoxia through Phosphorylation of Ago2” Nature 2013 May 01; 497: 383-387.
  22. Hsu MC, Hung WC, Yamaguchi H, Lim SO, Liao HW, Tsai CH, Hung MC. “Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway” Am J Cancer Res. 2016 Feb 15;6(3):628-38.
  23. Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC. “EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape” Cancer Res. 2016 Mar 1;76(5):1284-96.
  24. Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, Lee DF, Wang H, Wang Y, Chou CK, Hsu JM, Lai YJ, LaBaff AM, Ding Q, Ko HW, Tsai FJ, Tsai CH, Hortobagyi GN, Hung MC. “AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation” Cancer Res. 2016 Mar 15;76(6):1451-62.
  25. Ko HW, Lee HH, Huo L, Xia W, Yang CC, Hsu JL, Li LY, Lai CC, Chan LC, Cheng CC, Labaff AM, Liao HW, Lim SO, Li CW, Wei Y, Nie L, Yamaguchi H, Hung MC. “GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers” Oncotarget 2016 Aug 2; DOI: 10.18632/oncotarget.11008.
  26. Li CW*, Lim SO*, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. “Glycosylation and stabilization of programmed death ligand-1 suppresses T cell activity” †Nature Commun. 2016 Aug 30; 7:12632

*Co-first author  Selected as 2016: Signaling breakthroughs of the year by Sci Signaling

  1. Chang SS, Yamaguchi H, Xia W, Lim SO, Khotskaya Y, Wu Y, Chang WC, Liu Q, Hung MC. “Aurora A Kinase Activates YAP Signaling in Triple-Negative Breast Cancer” Oncogene 2016 Sep 5; doi: 10.1038/onc/2016.292.
  2. Lim SO*, Li CW*, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC. “Deubiquitination and stabilization of PD-L1 by CSN5” †Cancer Cell 2016 Dec 12; 30:1-15. Epub 2016 Nov 17 *Co-first author

      †Research Watch “Chronic inflammation promotes CSN5-mediated PD-L1 stabilization”. Cancer Discovery (DOI:10.1158/2159-8290. CD-RW2016-224) Dec 2, 2016.

      †Selected as 2016: Signaling breakthroughs of the year by Sci Signaling

      †Preview Y. Grinberg-Bleyer, S. Ghosh, “A novel link between inflammation and cancer” Cancer Cell 2016 Dec 12; 30: 829–830. DOI: 10.1016/j.ccell.2016.11.013

      †Editor’s choice “Inflammation helps tumors evade immune detection” Sci. Signaling 20 Dec 2016: Vol. 9, Issue 459, pp. ec300; DOI: 10.1126/scisignal.aam6078

  1. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton JK, Arun B, Hortobagyi GN, Hung MC. “PARP inhibitor upregulates PD-l1 expression and enhances cancer-associated immunosupression” Clin Cancer Res 2017 Feb 6. pii: clincanres.3215.2016. doi: 10.1158/1078-0432.CCR-16-3215. [Epub ahead of print]
  2. Li CW*, Lim SO*, Hsu JL, Hung MC. “Rational combination of immunotherapy for triple negative breast cancer treatment” Chin Clin Oncol. 2017 Oct; 6(5):54. Doi:10.21037/cco.2017.08.04. *Co-first author
  3. Nilsson MN, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. “Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with b-blockers” Sci Transl Med. 2017 Nov 8; 9(415). Doi:10.1126/scitranslmed.aao4307.
  4. Li CW*, Lim SO*, Chung EM, Kim YS, Andrew H. Park AH, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Horng H, Yeh T, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Yao J, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC. “Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1” †Cancer Cell 2018 Feb 12; 33(2):187-201. *Co-first author

      †Preview M. Salatino, MR. Girotti, GA Rabinovich, “Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer” Cancer Cell 2018 Feb 12; 33(2): 155-157.

  1. Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim M, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC. “Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer” Cancer Cell 2018 Apr 9;33(4):752-769.e8. doi: 10.1016/j.ccell.2018.02.012. Epub 2018 Mar 29.
  2. Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, Chen CT, Liao HW, Kuo CW, Khoo KH, Hsu JL, Li CW, Lim SO, Chang SS, Chen YC, Ren GX, Hung MC. “STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion” Nat Commun. 2018 May 15;9(1):1908. doi: 10.1038/s41467-018-04313-6.
  3. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH Hsu JL4, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC. “Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1” Mol Cell 2018 Aug 16;71(4):606-620.e7. doi: 10.1016/j.molcel.2018.07.030.
  4. Shao B, Li CW, Lim SO, Sun L, Lai YJ, Hou J, Liu C, Chang CW, Qiu Y, Hsu JM, Chan LC, Zha Z, Li H, Hung MC. “Deglycosylation of PD-L1 by 2-deoxyglucose reverse PARP inhibitor-induced immunosuprssion in triple-negative breast cancer” Am J Cancer Res. 2018 Sep 1;8(9):1837-1846.
  5. Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX. “Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade” Gut. 2019 Sep;68(9):1653-1666. doi: 10.1136/gutjnl-2019-318419.
  6. Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC. “IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion” J Clin Invest. 2019 Jul 15;129(8):3324-3338. doi: 10.1172/JCI126022.
  7. Kobayashi Y, Lim SO, Yamaguchi H. “Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer” Semin Cancer Biol. 2019 Dec 23; pii: S1044-579X(19)30406-7. doi: 10.1016/j.semcancer.2019.11.011
  8. Kim B, Sun R, Oh W, Kim AMJ, Schwarz JR, Lim SO. “Saccharide analog, 2-deoxy-D-glucose enhances 4-1BB mediated anti-tumor immunity via PD-L1 deglycosylation” Molecular Carcino. 2020 Mar 1; 1-10. doi: 10.1002/mc.23170.
  9. Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y, Chang SS, Yamaguchi H, Lee HH, Ke B, Chan LC, Hortobagyi GN, Yang L, Lin C, Yu D, Hung MC. “TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumor ferroptosis” J Clin Invest. 2021 Apr 15;131(8):139434. Doi: 10.1172/JCI139434.
  10. Sun R, Kim AMJ, Lim SO. “Glycosylation of Immune Receptors in Cancer” Cells 2021; 10, 1100. doi: 10.3390/cells10051100.
  11. Sun R, Kim AMJ, Murray A, Lim SO. “N-glycosylation Facilitates 4-1BB Membrane Localization by Avoiding Its Multimerization” Cells 2022; 11(1), 162. doi: 10.3390/cells1101062.
  12. Sun R, Lim SO. “FBXL20-mediated ubiquitination triggers the proteasomal degradation of 4-1BB” FEBS J. 2022 Feb 3; doi: 10.1111/febs.16383.
  13. Cha JH, Chan LC, Wang YN, Chu YY, Wang CH, Lee HH, Xia W, Shyu WC, Liu SP, Yao J, Chang CW, Cheng FR, Liu J, Lim SO, Hsu JL, Yang WH, Hortobagyi GN, Lin C, Yang L, Yu D, Jeng LB, Hung MC. “Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer” J Biol Chem. 2022 Apr;298(4):101817. doi: 10.1016/j.jbc.2022.101817. 
  14. Kim AMJ, Lim SO. “4-1BB: A promising target for cancer immunotherapy” Front Oncol. 2022 Sep 14;12:968360. doi: 10.3389/fonc.2022.968360.
  15. Oh W, Kim AMJ, Dhawan D, Kirkham PM, Ostafe R, Franco J, Aryal UK, Carnahan RH, Patsekin V, J Paul Robinson JP, Knapp DW, Lim SO. “Development of an anti-canine PD-L1 antibody and caninized PD-L1 mouse model as translational research tool for the study of immunotherapy in humans” Cancer Research Communications 2023 May; 3 (5):860-873
  16. Nie L, Wang YN, Hsu JM, Hou J, Chu YY, Chan LC, Huo L, Wei Y, Deng R, Tang J, Hsu YH, Ko HW, Lim SO, Huang K, Chen MK, Chiu TJ, Cheng CC, Fang YF, Li CW, Goverdhan A, Wu HJ, Lee CC, Wang WL, Hsu J, Chiao P, Wang SC, Hung MC. “Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells” Am J Cancer Res. 2023 Apr 15;13(4):1209-1239.
  17. Oh W, Kim AMJ, Dhawan D, Knapp DW, Lim SO. “Tumor cell-derived lactic acid inhibits the interaction of PD-L1 protein and PD-L1 antibody in the immune checkpoint blockade resistant tumor” bioRxiv 2023; doi: